about
Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritisPsoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?The Changing Face of Clinical Trials in Psoriatic Arthritis.International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trialsClues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review.Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesApplication of composite disease activity scores in psoriatic arthritis to the PRESTA data set.Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis.The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisQualifying unmet needs and improving standards of care in psoriatic arthritis.Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasound.Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris.Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the ClinicianComprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort.Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis.The OMERACT MRI inflammatory arthritis group: advances and future research priorities.The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands.An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas.Disease measurement--enthesitis, skin, nails, spine and dactylitis.Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.Update on research and future directions of the OMERACT MRI inflammatory arthritis group.MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis.Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.Patient involvement in outcome measures for psoriatic arthritis.GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting.Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA.Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis.Treating to target in psoriatic arthritis.Treat to target in psoriatic arthritis-evidence, target, research agenda.Therapy strategies in psoriatic arthritis.The involvement of the spine in psoriatic arthritis.Treating to target in psoriatic arthritis: how to implement in clinical practice.Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.The cost-effectiveness of tight control of inflammation in early psoriatic arthritis: Economic analysis of the TICOPA trial.
P50
Q24625936-1E4687FD-C408-463C-8045-B67EAE0A7F47Q26744032-5DEC32D1-F9C1-4C9A-84CF-19A036E0E3C8Q30235002-62F52952-34FB-4CE8-94A5-1BB0DCC83466Q30841346-F6F22BCB-DA44-4C1A-86E7-EDF97D3FA4C9Q33349975-909718CF-215B-4432-8E91-B567161E4B52Q33621489-BEBAA297-02DC-4720-A538-DA3DC8543F92Q33916770-E9089821-DB68-4513-B5E1-AC554FED7DB5Q34046790-16A37E00-872C-475A-881A-0194A7225D6FQ34409780-2EE00807-CD87-4468-B086-7D72DBBCEC70Q34630959-ED34A413-C9DF-4EF1-8650-86C0DF5F85CEQ34803582-37AAA871-9AED-4B86-88B9-887A77FCF5FBQ34803594-E948AD50-F72E-4C46-8F0C-410AD9FE76B6Q34905406-4675B822-5A50-410E-855A-6BF4C05BA5C6Q36059338-DC7A0430-90FD-4D5D-A1AE-EA0A58EE4FD6Q36094040-45D89EE5-2C44-4AEA-A480-EA534955C3C9Q36542790-9617EA79-10A0-4E6D-B88E-9D1E16153B1DQ37036355-661E92EA-4D29-4C45-BFCA-06B6AE05DCFEQ37427411-CFEB0240-6EF8-4979-A09B-D23BEF4C3F34Q37578144-761337A0-2F2D-4CDD-98CE-AFE806FF9092Q37578148-5D5B2F7F-4D3D-4FAB-A27D-301890D02796Q37662772-8C56ECEB-BC8E-480E-A008-33197C305B1EQ37805034-712C4ADF-CCAA-45D6-A54C-D0FB6F5A76A7Q37848550-0F9D8693-656D-4FE0-A03F-C28EA43BEBF1Q37882064-7C3DFE72-16B0-4412-9E55-BC91A016C946Q37897054-215A1559-BE29-43D2-82C7-4C5A68B39D7CQ37925320-17BFC3F7-4CC2-4E7F-B001-E898047BABEFQ38070245-6366A7E0-8DAC-4F0B-A693-8731E143D71AQ38184440-3934FE2D-B81C-4AC0-8063-0C80D14E849EQ38195568-1918BE5E-4D92-4F38-995C-B0E69EF48371Q38216633-581742D6-6AEB-40AB-89BA-D59FCD8D3D93Q38264280-2DEF6105-9867-43EF-B7D3-1B9BDB2E6AE1Q38264281-CAAFDEC5-01C8-4D89-854B-34F0A8FD2E80Q38264517-C440A21B-18CC-4B1C-AE5C-13F743E3372CQ38324935-6DC27DE7-C656-4BE3-A382-A0DAB6E4DC7CQ38436516-76599636-4BF8-4D6F-B708-F5F106DA1B03Q38608119-488C52A6-B2C9-4A66-AA91-DEBC4AB622B6Q38608256-8A8B27D0-11E0-410D-A670-EBC9579D5F20Q38670583-4D2C3FCB-B261-47C0-9428-9CCA33D2914EQ38672570-A66CE093-BEAF-4730-9AA9-69D9CBEEED57Q38678945-C0F36441-E9F4-45A9-B41D-EAA3478963E1
P50
description
British medical researcher
@en
researcher
@en-gb
wetenschapper
@nl
name
Laura C. Coates
@en
Laura C. Coates
@es
Laura Coates
@cy
Laura Coates
@en-gb
Laura Coates
@nl
Laura Coates
@sl
type
label
Laura C. Coates
@en
Laura C. Coates
@es
Laura Coates
@cy
Laura Coates
@en-gb
Laura Coates
@nl
Laura Coates
@sl
altLabel
Laura C Coates
@cy
Laura C Coates
@en
Laura C Coates
@en-gb
prefLabel
Laura C. Coates
@en
Laura C. Coates
@es
Laura Coates
@cy
Laura Coates
@en-gb
Laura Coates
@nl
Laura Coates
@sl
P184
P214
P244
P6366
P106
P1153
23479417900
P2031
2008-01-01T00:00:00Z
P21
P213
0000 0004 2700 8862
P214
P244
nb2015011019
P31
P4012
P496
0000-0002-4756-663X
P6178
01213606725.18
P6366
2460595590